University of Paris

Marking its 40th Anniversary, Bentley Systems Announces CEO Transition Plan

Retrieved on: 
Thursday, March 21, 2024
Manufacturing, Audio, Video, Other Technology, Software, Urban Planning, Networks, Internet, Building Systems, Electronic Commerce, Data Management, Architecture, Technology, Other Energy, Construction & Property, Utilities, Alternative Energy, Energy, Engineering, Cloud, Growth, ARR, Bentley Systems, Business, City, SAP, IPO, System, Quality of life, Senior, Marketing, BSY, OpenX, Multimedia, University of Paris, Management

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that effective July 1, 2024, Greg Bentley will transition from Bentley Systems’ CEO to Executive Chair of its Board of Directors.

Key Points: 
  • Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that effective July 1, 2024, Greg Bentley will transition from Bentley Systems’ CEO to Executive Chair of its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20240321537157/en/
    Bentley Systems CEO Greg Bentley will become Executive Chair on July 1, 2024.
  • (Photo: Business Wire)
    The announcement was made during the opening event for Bentley Systems’ new UK headquarters in the City of London, beginning the observance of the company’s 40th anniversary.
  • Nicholas Cumins said, “This year marks the 40th anniversary of the founding of Bentley Systems, at its essence a company of engineers for engineers.

Angeion Group Welcomes Maria José Azar-Baud as Global Collective Actions Expert

Retrieved on: 
Wednesday, March 13, 2024
Comparative law, European Parliament, Associate, Research, Paris-Saclay University, Assas, University, Sorbonne University, Doctor of Philosophy, European, Consumer protection, University of Paris, Management

PHILADELPHIA, March 13, 2024 /PRNewswire/ -- Angeion Group, a global provider of settlement administration and legal noticing services, proudly announces the appointment of Maria José Azar-Baud as Global Collective Actions Expert.

Key Points: 
  • PHILADELPHIA, March 13, 2024 /PRNewswire/ -- Angeion Group, a global provider of settlement administration and legal noticing services, proudly announces the appointment of Maria José Azar-Baud as Global Collective Actions Expert.
  • Maria José Azar-Baud, born in Argentina, brings a distinguished background to her role as Global Collective Actions Expert at Angeion Group.
  • Throughout her career, Maria José has authored over 80 contributions in multiple languages, focusing on class actions, collective actions, and group actions across various legal domains.
  • "We are thrilled to welcome Maria José Azar-Baud to Angeion Group as our Global Collective Actions Expert.

ACWA Awards $10,000 Water Law & Policy Scholarship

Retrieved on: 
Thursday, November 30, 2023
Public policy, HEC Paris, Conference, Water, University of Paris, Harvard Kennedy School, UN, Public affairs, ALS, ACWA, Economics, Sciences Po

INDIAN WELLS, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- The Association of California Water Agencies (ACWA) today announced the winner of its 2023 Stephen K. Hall Water Law & Policy scholarship.

Key Points: 
  • INDIAN WELLS, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- The Association of California Water Agencies (ACWA) today announced the winner of its 2023 Stephen K. Hall Water Law & Policy scholarship.
  • The scholarship was announced at the 2023 ACWA Fall Conference & Expo in Indian Wells, where water professionals from throughout California gather for programs and panel discussions on a variety of key water issues.
  • The scholarship was established in 2007 in honor of former ACWA Executive Director Steve Hall, who passed away in 2010 after a lengthy battle with ALS.
  • ACWA is a statewide association of public agencies whose more than 470 members are responsible for about 90% of the water delivered in California.

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

Retrieved on: 
Saturday, December 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Fever, Bispecific monoclonal antibody, Research, NYSE, Injection site reaction, ASH, CRS, Risk, Disease, Fatigue, Patient, Abstract, PFS, MRD, AbbVie, Follicular lymphoma, COVID-19, Exposition, Neutropenia, ORR, University of Paris, Diarrhea, APHP, ABBV, Society, Overalls, Lymphoma, Cytokine release syndrome, Pharmaceutical industry

An estimated 85 percent and 74 percent of patients who experienced a CR remained in response at 12 and 18 months, respectively.

Key Points: 
  • An estimated 85 percent and 74 percent of patients who experienced a CR remained in response at 12 and 18 months, respectively.
  • Safety findings were consistent with previous epcoritamab trials, and epcoritamab was generally well tolerated.
  • TEAEs leading to treatment discontinuation occurred in 19 percent of patients, and Grade 5 TEAEs occurred in 13 patients (10 percent).
  • “The data presented at ASH reinforce what we have seen from our epcoritamab research and believe that this investigational bispecific antibody could potentially represent an important treatment option for patients living with relapsed or refractory follicular lymphoma.

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Retrieved on: 
Saturday, December 9, 2023
Fever, NYSE, Cytokine release syndrome, Injection site reaction, Food, European Medicines Agency, Type, Incidence, Lymphoid leukemia, ASH, CRS, Disease, Risk, Clinical trial, Hematology, Fatigue, EMA, Patient, European, BTD, Data analysis, FDA, AbbVie, Follicular lymphoma, COVID-19, Neutropenia, ORR, University of Paris, Diarrhea, Death, APHP, ABBV, Genmab, Pharmaceutical industry

NORTH CHICAGO, Ill., Dec. 9, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) previously treated with two or more prior therapies experienced strong and durable responses with high overall response (ORR) and complete response (CR) rates when treated with epcoritamab (DuoBody® CD3xCD20), an investigational, subcutaneously administered T-cell engaging bispecific antibody. More than half of patients who responded to treatment in the study remained responsive to treatment at the time of data analysis (i.e., median duration of response was not reached). Data from the dose-expansion cohort of the Phase 1/2 EPCORE™ NHL-1 clinical trial are being shared during a poster presentation on Saturday, December 9 at 5:30 PM PT at the ASH congress in San Diego, California. Updated data from this study include an optimized, step-up dosing schedule showing reduced incidence and severity of cytokine release syndrome (CRS), a notable side effect from immune-engaging cancer treatments.

Key Points: 
  • More than half of patients who responded to treatment in the study remained responsive to treatment at the time of data analysis (i.e., median duration of response was not reached).
  • "These data at this year's ASH further build our confidence in epcoritamab's treatment potential as well as development for earlier patient treatment."
  • An estimated 85% and 74% of patients who experienced a CR remained responsive to treatment at 12 and 18 months, respectively.
  • TEAEs leading to treatment discontinuation occurred in 19% of patients, and death related to TEAEs occurred in 13 patients (10%).

Alpenglow Biosciences, Inc. Sponsors Dinner Lecture titled "Decoding Immune Exclusion and Tumor Evasion in the TME", featuring Dr. Laura Dillon, PhD of Incendia Therapeutics

Retrieved on: 
Monday, October 30, 2023
Neoplasm, 3D, University of Paris, Pathology, MPH, Society for Immunotherapy of Cancer, Doctor of Philosophy, Phenotype, Research, Translational medicine, Alpenglow, SITC, Immunotherapy, Immune system, Dillon, DRS, Tumor microenvironment, Society, Therapy, TME, Immunology, Patient, SAN, Medical imaging, MD, Gas lighting, Cancer

The dinner lecture will take place on November 4th in San Diego's historic Gaslamp district.

Key Points: 
  • The dinner lecture will take place on November 4th in San Diego's historic Gaslamp district.
  • The evening will bring together thought leaders in industry and promises to be an informative and engaging exploration of the complexities of immune exclusion within the tumor microenvironment (TME) and its impact on cancer therapy.
  • In addition to Dr. Dillon, the panelists will include Professor Wolf H. Fridman, MD, PhD, Professor Emeritus of Immunology at University Paris Cité, Paris, France.
  • Dr. Fridman is a world-renowned expert on the role of the immune system in combating human tumors.

Virology Education Presents the Demystifying Long COVID-19 International Conference 2023 7-9 December 2023

Retrieved on: 
Thursday, October 19, 2023
Health, Infectious Diseases, COVID-19, General Health, Research, Science, WHO, Harvard Medical School, COVID, University of Paris, SARS-CoV-2, Face, University of California, Sheba Medical Center, Inflammation, Light, Westminster Hospital, Disease, Caregiver, Risk, University, Public, Cone Health Women's Hospital, Patient, Hospital, Pharmaceutical industry, Medical device, Vaccine, Nursing

Long COVID - a multisystem condition that significantly burdens individuals and public health, experienced by approximately 10-20 % of people infected by SARS-CoV-2.

Key Points: 
  • Long COVID - a multisystem condition that significantly burdens individuals and public health, experienced by approximately 10-20 % of people infected by SARS-CoV-2.
  • This new initiative provides a global platform for this vital cross-disciplinary discussion.
  • What do we know about the global prevalence, risk factors, and long-term evolution of long COVID?
  • How to improve the care pathways in the light of what is organized in different countries?

NanoString Platforms Advance Groundbreaking Studies of Immune Response in Pig-to-Human Organ Transplants

Retrieved on: 
Monday, August 21, 2023
Health, Surgery, Genetics, Other Science, Research, Science, Biotechnology, Xenotransplantation, Human, Allo, University, Paris Institute for Advanced Study, University of Paris, Neutrophil, Doctor of Philosophy, Macrophage, The Wall Street Journal, NYU, Hope, DRS, NK, Brain death, Transplant, System, Monocyte, Animal, MD, Patient, The New York Times, Organ transplantation, Kidney, NanoString Technologies, Medical research, Vaccine, Dentistry, Lancet

The groundbreaking study featured in the August issue and an accompanying commentary of The Lancet medical journal produced fundamental new data on the first pig-to-human organ transplants.

Key Points: 
  • The groundbreaking study featured in the August issue and an accompanying commentary of The Lancet medical journal produced fundamental new data on the first pig-to-human organ transplants.
  • Scientists used the nCounter Human Organ Transplant Panel , a process NanoString developed with the Banff International Classification Consortium.
  • The GeoMx Digital Spatial Profiler was used next to isolate the immune response to specific regions of the kidney.
  • “We congratulate Dr. Loupy and his extended team on their findings and celebrate the on-going successful studies in humans.”

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Retrieved on: 
Friday, July 21, 2023
DLBCL, Lymphatic system, Advanced Therapy Medicinal Product, NHL, B-cell lymphoma, Committee, EMA, Patient, AbbVie, European, B cell, Committee for Medicinal Products for Human Use, University of Paris, European Medicines Agency, APHP, Disease, European Commission, Safety, CHMP, Vaccine, Pharmaceutical industry, Genmab

The final European Commission decision on the indication for epcoritamab is anticipated later this year.

Key Points: 
  • The final European Commission decision on the indication for epcoritamab is anticipated later this year.
  • The primary endpoint of the study was overall response rate, as assessed by an independent review committee (63.1 percent).
  • It is the most common type of B-cell NHL worldwide and accounts for approximately 30 percent of all global cases.
  • The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Retrieved on: 
Friday, July 21, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, DLBCL, Lymphatic system, Advanced Therapy Medicinal Product, NHL, B-cell lymphoma, Committee, EMA, Patient, AbbVie, European, B cell, Committee for Medicinal Products for Human Use, University of Paris, European Medicines Agency, APHP, Disease, European Commission, Safety, CHMP, Vaccine, Pharmaceutical industry, Genmab

The final European Commission decision on the indication for epcoritamab is anticipated later this year.

Key Points: 
  • The final European Commission decision on the indication for epcoritamab is anticipated later this year.
  • The primary endpoint of the study was overall response rate, as assessed by an independent review committee (63.1 percent).
  • It is the most common type of B-cell NHL worldwide and accounts for approximately 30 percent of all global cases.
  • The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.